Omeros Corp
OMER11.230USD
+0.490+4.56%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
786.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Omeros Corp Unternehmen
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Omeros Corp Informationen
BörsenkürzelOMER
Name des UnternehmensOmeros Corp
IPO-datumOct 08, 2009
CEODemopulos (Gregory A)
Anzahl der mitarbeiter202
WertpapierartOrdinary Share
GeschäftsjahresendeOct 08
Addresse201 Elliott Avenue West
StadtSEATTLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl98119
Telefon12066765000
Websitehttps://www.omeros.com/
BörsenkürzelOMER
IPO-datumOct 08, 2009
CEODemopulos (Gregory A)
Führungskräfte von Omeros Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. George A. Gaitanaris, M.D., Ph.D.
Dr. George A. Gaitanaris, M.D., Ph.D.
Vice President - Science, Chief Scientific Officer
Vice President - Science, Chief Scientific Officer
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
Dr. J. Steven Whitaker, M.D., J.D.
Dr. J. Steven Whitaker, M.D., J.D.
Vice President - Clinical Development
Vice President - Clinical Development
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Dec 5
Aktualisiert: Fri, Dec 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ingalls & Snyder LLC (Asset Management)
5.79%
BlackRock Institutional Trust Company, N.A.
5.78%
The Vanguard Group, Inc.
5.66%
UBS Financial Services, Inc.
3.13%
Stifel, Nicolaus & Company, Incorporated
2.56%
Andere
77.08%
Aktionäre
Aktionäre
Anteil
Ingalls & Snyder LLC (Asset Management)
5.79%
BlackRock Institutional Trust Company, N.A.
5.78%
The Vanguard Group, Inc.
5.66%
UBS Financial Services, Inc.
3.13%
Stifel, Nicolaus & Company, Incorporated
2.56%
Andere
77.08%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
18.92%
Investment Advisor/Hedge Fund
16.92%
Hedge Fund
7.52%
Research Firm
5.37%
Individual Investor
2.74%
Bank and Trust
0.86%
Insurance Company
0.12%
Pension Fund
0.07%
Andere
47.47%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
254
35.16M
49.59%
+4.61M
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ingalls & Snyder LLC (Asset Management)
4.11M
5.79%
+123.69K
+3.11%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.10M
5.78%
+401.97K
+10.88%
Sep 30, 2025
The Vanguard Group, Inc.
3.35M
4.72%
+63.38K
+1.93%
Sep 30, 2025
UBS Financial Services, Inc.
701.35K
0.99%
-157.44K
-18.33%
Sep 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.81M
2.56%
+289.38K
+19.00%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.59M
2.25%
+507.73K
+46.75%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.54M
2.17%
+165.50K
+12.08%
Sep 30, 2025
Two Sigma Investments, LP
1.51M
2.13%
+418.50K
+38.29%
Sep 30, 2025
Polar Asset Management Partners Inc.
1.50M
2.11%
+1.50M
--
Sep 30, 2025
Demopulos (Gregory A. M.D.)
1.43M
2.01%
-600.00K
-29.60%
Oct 13, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.94%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
ProShares UltraPro Russell2000
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.94%
iShares Micro-Cap ETF
Anteil0.09%
Invesco Nasdaq Biotechnology ETF
Anteil0.05%
ProShares Ultra Nasdaq Biotechnology
Anteil0.05%
ProShares UltraPro Russell2000
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.02%
ProShares Hedge Replication ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
